ALECTOR INC
NASDAQ: ALEC (Alector, Inc.)
Last update: 20 hours ago2.14
0.00 (0.00%)
| Previous Close | 2.14 |
| Volume | 4,699,039 |
| Price / Sales | 19.61 |
| Price / Book | 19.57 |
| 52 Weeks Range |
| Profit Margin | -139.74% |
| Operating Margin (TTM) | -1,216.52% |
| Diluted EPS (TTM) | -1.26 |
| Quarterly Revenue Growth (YOY) | -76.90% |
| Total Debt/Equity (MRQ) | 43.39% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | -229.34 M |
| Levered Free Cash Flow (TTM) | -92.86 M |
| Return on Assets (TTM) | -17.22% |
| Return on Equity (TTM) | -90.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Alector, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 0.5 |
| Average | -2.13 |
|
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.61% |
| % Held by Institutions | 80.74% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merck & Co., Inc. | 30 Jun 2026 | 3,545,719 |
| Spruce Street Capital Lp | 30 Jun 2026 | 2,101,068 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BERKLEY NEIL LINDSAY | - | 2.51 | -29,251 | -73,420 |
| ROSENTHAL ARNON | - | 2.51 | -72,606 | -182,241 |
| WONG-SARAD GRACE | - | 2.56 | -9,446 | -23,666 |
| Aggregate Net Quantity | -111,303 | |||
| Aggregate Net Value ($) | -279,327 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 2.54 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WONG-SARAD GRACE | Officer | 04 Sep 2026 | Automatic sell (-) | 3,625 | 2.46 | 8,918 |
| WONG-SARAD GRACE | Officer | 03 Sep 2026 | Sell (-) | 5,165 | 2.51 | 12,964 |
| BERKLEY NEIL LINDSAY | Officer | 03 Sep 2026 | Sell (-) | 29,251 | 2.51 | 73,420 |
| ROSENTHAL ARNON | Officer | 03 Sep 2026 | Sell (-) | 72,606 | 2.51 | 182,241 |
| WONG-SARAD GRACE | Officer | 02 Sep 2026 | Automatic sell (-) | 656 | 2.72 | 1,784 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |